Puma Biotechnology (PBYI) to Release Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Puma Biotechnology to post earnings of ($0.16) per share for the quarter. Puma Biotechnology has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.07). The company had revenue of $72.20 million during the quarter, compared to the consensus estimate of $73.22 million. Puma Biotechnology had a return on equity of 58.21% and a net margin of 9.16%. On average, analysts expect Puma Biotechnology to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Puma Biotechnology Trading Up 1.0 %

NASDAQ:PBYI opened at $5.07 on Wednesday. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.23. The stock has a market capitalization of $244.42 million, a PE ratio of 11.02, a price-to-earnings-growth ratio of 2.86 and a beta of 1.28. The firm’s 50 day moving average is $5.43 and its 200 day moving average is $4.64. Puma Biotechnology has a 12 month low of $2.13 and a 12 month high of $7.73.

Analyst Ratings Changes

PBYI has been the topic of a number of research reports. StockNews.com cut shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Wednesday, April 10th. HC Wainwright lowered their price target on shares of Puma Biotechnology from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, March 1st.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.